Immunotherapy for osteosarcoma: Where do we go from here?

The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review

(2018) A.F. de Groot et al.   CANCER TREATMENT REVIEWS

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

(2017) Hussein A Tawbi et al.   LANCET ONCOLOGY

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Preclinical Testing of an Oncolytic Parvovirus: Standard Protoparvovirus H-1PV Efficiently Induces Osteosarcoma Cell Lysis In Vitro

(2017) Carsten Geiss et al.   Viruses-Basel

Targeting the PD-1 pathway in pediatric solid tumors and brain tumors

(2017) Lars Wagner et al.   OncoTargets and Therapy

DNA Damage and Repair Biomarkers of Immunotherapy Response

(2017) Kent W. Mouw et al.   Cancer Discovery

Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1

(2017) Emanuela Palmerini et al.   Oncotarget

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial

(2017) Anne Gomez-Brouchet et al.   OncoImmunology

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies

(2016) Chuang Sun et al.   BLOOD

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

(2016) Haidong Tang et al.   CANCER CELL

Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy

(2016) Yayan T. Sundara et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α

(2016) Yana G. Najjar et al.   CLINICAL CANCER RESEARCH

Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?

(2016) Lucia Festino et al.   DRUGS

Progress and opportunities for immune therapeutics in osteosarcoma

(2016) Christina K Lettieri et al.   Immunotherapy

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

(2016) Kelly D Moynihan et al.   NATURE MEDICINE

IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

(2016) David H. Munn et al.   TRENDS IN IMMUNOLOGY

TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression

(2016) Audrey Lamora et al.   Journal of Clinical Medicine

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy

(2016) Maarten Swart et al.   Frontiers in Oncology

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

(2016) Pratistha Koirala et al.   Scientific Reports

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors

(2015) M. S. Merchant et al.   CLINICAL CANCER RESEARCH

Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma

(2015) Nabil Ahmed et al.   JOURNAL OF CLINICAL ONCOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions

(2015) Danielle M. Lussier et al.   JOURNAL OF IMMUNOTHERAPY

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

(2015) C Krupka et al.   LEUKEMIA

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma

(2015) Michael Roth et al.   PEDIATRIC BLOOD & CANCER

Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines

(2015) Theodore S. Nowicki et al.   PEDIATRIC RESEARCH

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Overcoming T cell exhaustion in infection and cancer

(2015) Kristen E. Pauken et al.   TRENDS IN IMMUNOLOGY

Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

(2015) M. Callea et al.   Cancer Immunology Research

Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma

(2015) Danielle M Lussier et al.   Journal for ImmunoTherapy of Cancer

A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

(2015) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+ HLA-DRlo/neg) found in aggressive pediatric sarcoma patients

(2015) Pooja Hingorani et al.   Journal for ImmunoTherapy of Cancer

Immunotherapy of Childhood Sarcomas

(2015) Stephen S. Roberts et al.   Frontiers in Oncology

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas

(2015) Xin Huang et al.   PLoS One

Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors

(2014) J. Fu et al.   CANCER RESEARCH

Regulatory T cells in cancer immunotherapy

(2014) Hiroyoshi Nishikawa et al.   CURRENT OPINION IN IMMUNOLOGY

The Oncolytic Adenovirus Δ24-RGD in Combination With Cisplatin Exerts a Potent Anti-Osteosarcoma Activity

(2014) Naiara Martinez-Velez et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression

(2014) Damya Laoui et al.   Frontiers in Immunology

Exomics and immunogenics

(2014) Stéphane Champiat et al.   OncoImmunology

Osteosarcoma treatment – Where do we stand? A state of the art review

(2013) Anja Luetke et al.   CANCER TREATMENT REVIEWS

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

(2013) Wim H.J. Kruit et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

(2013) Johan Vansteenkiste et al.   JOURNAL OF CLINICAL ONCOLOGY

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

(2013) Rikke B. Holmgaard et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group

(2013) Brenda Weigel et al.   PEDIATRIC BLOOD & CANCER

Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines

(2013) N. Hacohen et al.   Cancer Immunology Research

Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma

(2012) Nourredine Himoudi et al.   Clinical & Translational Oncology

Anti-TGF-β Antibody Combined with Dendritic Cells Produce Antitumor Effects in Osteosarcoma

(2012) Masanori Kawano et al.   CLINICAL ORTHOPAEDICS AND RELATED RESEARCH

Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group

(2012) David Ebb et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity

(2011) Sophie R. Sierro et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group

(2011) Suman Malempati et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

(2010) W. Peng et al.   CLINICAL CANCER RESEARCH

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma

(2009) Hiroshi Urakawa et al.   CLINICAL & EXPERIMENTAL METASTASIS

The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

(2009) M. A. Cheever et al.   CLINICAL CANCER RESEARCH

Cyclophosphamide and cancer: golden anniversary

(2009) Ashkan Emadi et al.   Nature Reviews Clinical Oncology

Killer Dendritic Cells Link Innate and Adaptive Immunity against Established Osteosarcoma in Rats

(2008) C. Chauvin et al.   CANCER RESEARCH

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy

(2008) Karl S. Peggs et al.   IMMUNOLOGICAL REVIEWS

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION

Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

(2008) Paul A. Meyers et al.   JOURNAL OF CLINICAL ONCOLOGY